Vorinostat is victorious in GVHD prevention

Shernan G. Holtan; Daniel J. Weisdorf

doi:10.1182/blood-2017-08-802249

Vorinostat is victorious in GVHD prevention

Shernan G. Holtan, Daniel J. Weisdorf

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Abstract

In this issue of Blood, Choi et al describe the clinical efficacy of histone deacetylase inhibitor (HDACi) vorinostat in the prevention of severe acute graft-versus-host disease (aGVHD) in a high-risk setting: myeloablative, unrelated-donor allogeneic hematopoietic cell transplantation (HCT).¹

Original language	English (US)
Pages (from-to)	1690-1691
Number of pages	2
Journal	Blood
Volume	130
Issue number	15
DOIs	https://doi.org/10.1182/blood-2017-08-802249
State	Published - Oct 12 2017

Bibliographical note

Publisher Copyright:
© 2017 by The American Society of Hematology.

Access

10.1182/blood-2017-08-802249

OpenUrl availability

Full text

Cite this

@article{4cb183ffaa0e4a9b85668ef143b09924,

title = "Vorinostat is victorious in GVHD prevention",

abstract = "In this issue of Blood, Choi et al describe the clinical efficacy of histone deacetylase inhibitor (HDACi) vorinostat in the prevention of severe acute graft-versus-host disease (aGVHD) in a high-risk setting: myeloablative, unrelated-donor allogeneic hematopoietic cell transplantation (HCT).1",

author = "Holtan, {Shernan G.} and Weisdorf, {Daniel J.}",

note = "Publisher Copyright: {\textcopyright} 2017 by The American Society of Hematology.",

year = "2017",

month = oct,

day = "12",

doi = "10.1182/blood-2017-08-802249",

language = "English (US)",

volume = "130",

pages = "1690--1691",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "15",

}

TY - JOUR

T1 - Vorinostat is victorious in GVHD prevention

AU - Holtan, Shernan G.

AU - Weisdorf, Daniel J.

PY - 2017/10/12

Y1 - 2017/10/12

N2 - In this issue of Blood, Choi et al describe the clinical efficacy of histone deacetylase inhibitor (HDACi) vorinostat in the prevention of severe acute graft-versus-host disease (aGVHD) in a high-risk setting: myeloablative, unrelated-donor allogeneic hematopoietic cell transplantation (HCT).1

AB - In this issue of Blood, Choi et al describe the clinical efficacy of histone deacetylase inhibitor (HDACi) vorinostat in the prevention of severe acute graft-versus-host disease (aGVHD) in a high-risk setting: myeloablative, unrelated-donor allogeneic hematopoietic cell transplantation (HCT).1

UR - http://www.scopus.com/inward/record.url?scp=85031309760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031309760&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-08-802249

DO - 10.1182/blood-2017-08-802249

M3 - Comment/debate

C2 - 29025718

AN - SCOPUS:85031309760

SN - 0006-4971

VL - 130

SP - 1690

EP - 1691

JO - Blood

JF - Blood

IS - 15

ER -

Vorinostat is victorious in GVHD prevention

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this